PEMF for
Post-Mastectomy Pain.

August 2026 · 11 min read · Oncology Rehabilitation Protocol

Post-Mastectomy Pain Syndrome: Definition and Scope

Post-mastectomy pain syndrome (PMPS) is a chronic neuropathic pain condition defined as pain persisting beyond 3 months after breast surgery — including mastectomy, lumpectomy, breast-conserving surgery, or axillary lymph node dissection (ALND) — that is not attributable to infection, recurrence, or other identifiable cause. It affects 20–50% of breast cancer survivors, representing one of the largest single-condition neuropathic pain populations globally.

The primary nerves involved are the intercostobrachial nerve (ICBN) — a purely sensory branch of T2 that is transected or stretched in virtually all axillary dissections — and the medial and lateral pectoral nerves, thoracic intercostal nerves (T3–T6), and long thoracic nerve. The resulting pain is typically burning, electric, or tight in quality, involving the anterior chest wall, axilla, ipsilateral arm, or shoulder, and is worsened by arm elevation and chest wall pressure.

Why PMPS Remains Undertreated

Three converging factors drive the persistent treatment gap:

1. Hormonal treatment contraindication. The majority of PMPS patients are hormone receptor-positive (HR+) breast cancer survivors on aromatase inhibitors or tamoxifen. These drugs compound musculoskeletal pain (aromatase inhibitor-associated arthralgia affects 50% of users) and create a paradox: HRT — the most effective intervention for estrogen-withdrawal pain — is absolutely contraindicated. PEMF provides a non-hormonal analgesic pathway.
2. Opioid limitation. Opioids have poor efficacy for neuropathic pain, high addiction liability, and interact with the fatigue and cognitive impairment common in cancer survivors. Philippines opioid prescribing for cancer pain is heavily regulated under PDEA-DDB protocols, creating practical access barriers.
3. Gabapentinoid tolerance. Gabapentin and pregabalin provide partial relief (30–50% responders) but produce sedation, weight gain, and dizziness that disproportionately affect cancer survivors managing treatment-related fatigue.

Average PMPS pain NRS is 5.1/10, with severe impact on shoulder function, sleep quality, and return to work. Despite this, systematic management protocols for PMPS remain absent from most Philippine oncology follow-up programs — pain is often attributed to "normal post-surgical discomfort" at routine oncology reviews.

PEMF Mechanism in PMPS

Five parallel mechanisms explain PEMF's therapeutic action in the PMPS context:

• Intercostobrachial nerve territory neuromodulation — 8–25 Hz PEMF applied to the anterior chest wall and axillary region raises the action potential threshold of residual ICBN axons, reducing spontaneous ectopic discharge from neuroma formation at transection sites.
• Adenosine-A2A/substance P suppression — as documented in the core PMC11914662 dataset (n=91, 36%/55%), adenosine receptor activation reduces substance P and CGRP in the dorsal horn — directly applicable to the spinal cord segments (T2–T6) processing PMPS afferent input.
• Scar tissue and radiation fibrosis modulation — PEMF-induced collagen synthesis regulation (documented in wound healing RCTs) softens surgical scar and radiation-induced fibrotic tissue that mechanically compresses residual nerve endings. This addresses the tissue-level pain generator, not only the neural one.
• Central sensitization modulation — PMPS frequently involves central sensitization of the thoracic and cervical dorsal horn, identical to the mechanism seen in CRPS. PEMF's documented anti-central sensitization effect (via NF-κB suppression and glial cell modulation) addresses this component.
• Shoulder joint and rotator cuff protection — axillary dissection and radiation cause shoulder dysfunction in 30–40% of survivors (adhesive capsulitis, rotator cuff tendinopathy). PEMF's established efficacy for frozen shoulder and rotator cuff pathology (covered in separate protocols) directly addresses this comorbid pain source.

Clinical Evidence Base

Clinical Protocol: Three-Phase Approach

Pre-Treatment Requirements

• Oncology clearance confirming no active breast malignancy in the treatment field (mandatory)
• Wound healing complete — minimum 3 months post-surgery or 6 weeks post-radiation before initiating PEMF
• Baseline NRS, DASH (Disabilities of Arm, Shoulder and Hand) score, and shoulder ROM assessment

Phase 1 — Neuropathic Anti-Inflammatory (Weeks 1–4, 3× weekly)

• Frequency: 8–25 Hz
• Coil placement: Anterior chest wall (T2–T6 intercostal zone) + axillary region; avoid active port-a-cath or tissue expander overlay
• Session duration: 30–35 minutes
• Goal: Reduce ectopic ICBN discharge; suppress substance P at T2–T6 dorsal horn; begin scar tissue softening

Phase 2 — Central Sensitization & Shoulder Rehabilitation (Weeks 5–8, 2× weekly)

• Frequency: 25–50 Hz
• Coil placement: Chest wall + ipsilateral shoulder (rotator cuff / glenohumeral zone); cervical if cervicogenic component identified
• Session duration: 35–40 minutes
• Goal: Modulate central sensitization; address shoulder capsulitis and rotator cuff tendinopathy; improve arm elevation tolerance

Phase 3 — Maintenance (Ongoing, 1–2× monthly)

• Frequency: 8–50 Hz (symptom-guided)
• Goal: Prevent central sensitization recurrence; manage aromatase inhibitor-associated arthralgia as ongoing adjunct
• Multidisciplinary coordinate: Phrysio for shoulder mobilization; lymphedema specialist if ALND-related lymphedema coexists

PMPS Pain Subtypes and PEMF Response

Philippines Market Context

Breast cancer is the most common female malignancy in the Philippines, accounting for approximately 35,000 new diagnoses per year. With 5-year survival rates improving to 70–80% in hospital-based tertiary care, the Philippines now has an estimated 250,000–350,000 breast cancer survivors — a population growing by approximately 25,000 annually as treatment access improves under PhilHealth cancer benefit packages.

Applying a conservative 25% PMPS prevalence to this population yields 60,000–85,000 Filipino breast cancer survivors currently living with chronic post-mastectomy pain. The vast majority are managing this pain with inadequate tools: gabapentin at partial efficacy, unregulated opioid access, or no treatment at all. HRT is contraindicated in >80% of survivors (HR+ status). This creates one of the most clearly defined unmet-need populations in the Philippine pain management landscape.

The market position is further strengthened by the aromatase inhibitor arthralgia burden: 50% of the ~200,000 HR+ survivors on AI therapy develop significant joint pain as a treatment side effect — a condition for which PEMF provides a non-hormonal, non-drug adjunct directly aligned with oncology treatment goals.

Contraindications and Safety

• Absolute: Active breast malignancy in or adjacent to the treatment field — oncology clearance is mandatory before every treatment series; pacemaker or ICD; active infection at treatment site
• Relative (position coils away from): Metallic port-a-cath or implanted drug delivery device — maintain ≥5 cm distance; tissue expander with integrated magnet (verify expander type pre-treatment); breast reconstruction prosthesis — most are MRI-compatible and PEMF-safe, but confirm with reconstructive surgeon
• Radiation therapy: Do not apply PEMF to actively irradiated fields; safe to commence ≥6 weeks after radiation therapy completion
• Lymphedema: PEMF is not contraindicated in lymphedema; manual lymphatic drainage should precede PEMF sessions in affected limb to optimize tissue conditions
• Critical reminder: PEMF does not treat breast cancer. All treatment decisions must remain coordinated with the patient's oncology team. PEMF is an adjunct pain management modality for survivors in remission or active treatment with oncology approval

What This Means for Clinic Investors

Post-mastectomy pain syndrome represents a strategically positioned market segment: large (60,000–85,000 patients in the Philippines), underserved, well-defined, and generating strong patient motivation for ongoing treatment. These are health-literate, treatment-adherent patients — breast cancer survivors who have completed rigorous oncology protocols and are highly engaged with their post-treatment health management.

The oncology rehabilitation positioning also creates a premium referral pathway: breast surgeons, medical oncologists, and radiation oncologists are natural referral partners who typically have no non-pharmaceutical solution to offer for PMPS. A formal oncology rehabilitation protocol — with mandatory oncology clearance, structured outcome tracking, and oncologist communication — positions a PEMF clinic as a credible specialist partner rather than an alternative-medicine provider.

At ₱1,500–₱2,500 per session and 16–24 sessions in a primary course, plus 1–2 maintenance sessions per month for ongoing AI arthralgia management, each committed PMPS patient generates ₱24,000–₱60,000 in primary course revenue plus ₱18,000–₱60,000 annually in maintenance visits. At 70+ Israeli clinics (population: 9M) now expanding to the Philippines, oncology rehabilitation is a key growth segment for the second expansion wave.